secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055649
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reports Q1 net loss $54.4M; MM120 GAD trial hits key endpoint, FDA Breakthrough Therapy
--------------------------------------------------------------------------------

- Net loss $54.4M Q1'24 (vs $24.8M); includes $27.7M warrant fair value change. R&D $11.7M, G&A $10.5M.
- Cash $252.3M at Mar 31 (vs $99.7M Dec'23). Expects funding into 2026.
- Phase 2b MM120 GAD: 7.7-pt HAM-A improvement vs placebo (p<0.003), 65% response, 48% remission at Week 12.
- FDA Breakthrough Therapy for MM120 in GAD. Phase 3 initiation planned H2 2024.
- CFO Schond Greenway departed May 3. Executive search for new CFO underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/0000950170-24-055649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/mnmd-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer